BioSpace News Archive

Puma Biotechnology, Inc., a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Alan H. Auerbach, will refer to in meetings beginning Monday, January 9, 2023.

Selecta Biosciences, Inc. and Astellas Pharma Inc. today announced an exclusive licensing and development agreement for IdeXork (Xork).

Elevation Oncology, Inc. today announced that Joseph Ferra , Interim Chief Executive Officer and Chief Financial Officer of Elevation Oncology, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 9:45 am PT.

Takeda (TSE:4502/NYSE:TAK) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD).

Precision BioSciences today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023.

Clinical-stage pharmaceutical company ENA Respiratory has been awarded a $4.38 million USD agreement from the U.S. Department of Defense to support ongoing research and development of INNA-051, a clinical stage first-in-class broad-spectrum antiviral innate immunomodulator, administered intranasally for the prophylaxis of respiratory viral infections and their complications.

Cerevance today announced positive results from its Phase 1 study of CVN766 in healthy subjects.

Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) today announced that the first patient has been dosed in the Phase 1 investigator sponsored clinical trial of VCN-01, an intravenous oncolytic adenovirus, for patients with high-grade brain tumors who are scheduled for surgical resection.

Alimera Sciences, Inc. today announced the appointment of pharma financial veteran Russell L. Skibsted, as Senior Vice President and Chief Financial Officer (“CFO”), effective today, January 9, 2023.

PROCEPT® BioRobotics Corporation today reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2022.